Management of Vitiligo with Topical JAK Inhibitor Therapy: An Evidence-Based Review
Published: 11 October 2022| Version 3 | DOI: 10.17632/ngwr9gns95.3
Vitiligo is an acquired progressive skin disorder characterized by hypopigmentation due to absence of functional melanocytes affecting up to 1% of the general population. Initial treatment typically involves the use of topical and phototherapy; however, experimental agents such as topical Janus kinase inhibitors (JAKi) are being explored as a treatment option. This systematic review examines the use of topical JAKi therapies in vitiligo, with a focus on treatment efficacy.